Navelbine and Herceptin combination as first line therapy for HER 2- overexpressing metastatic breast cancer is a highly active and safe regimen. Final results of multinational trial

    Activity: Talk or presentationConference presentation


    Contributors: Kellokumpu-Lehtinen Pirkko / Tieteelliset esitykset
    Period3 Dec 2003
    Event title26th Annual San Antonio Breast Cancer Symposium
    Event typeOther
    Degree of RecognitionInternational